Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1238351 | 0.98 | ATM (0.58) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL12480829 | 0.97 | ATM (0.57) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL13339837 | 0.94 | HDAC3 (0.56) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL3491381 | 0.93 | HDAC3 (0.55) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL4782352 | 0.91 | HDAC3 (0.54) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL30884498 | 0.91 | HDAC3 (0.54) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL3231898 | 0.89 | HDAC3 (0.53) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| Trifluoroacetic Acid SCHEMBL29963847 | 0.88 | ATM (0.52) | ATMSIGMAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL11114131 | 0.85 | ATM (0.64) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL619987 | 0.85 | ATM (0.64) | ATMSIGMAR1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| CN-119371410-A | Chromone spiro compound and preparation method and application thereof | 中国药科大学 | 2025-01-28 | — | — | CN | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-3897832-B1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023170699-A1 | TRICYCLIC SPIRO[CHROMANE-2,4'-PIPERIDIN]-4(3H)-ONE WITH 1,3,4-OXADIAZOLE LINKERS COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF. | GHATPANDE NITIN (IN) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170699-A1 | TRICYCLIC SPIRO[CHROMANE-2,4'-PIPERIDIN]-4(3H)-ONE WITH 1,3,4-OXADIAZOLE LINKERS COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF. | GHATPANDE NITIN (IN) | 2023-09-14 | — | — | WO | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2022-02-03 | — | — | US | disclosed |
| WO-1997037630-A2 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)-4(3H)-ONE DERIVATIVES, ACID ADDITION SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997037630-A2 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)-4(3H)-ONE DERIVATIVES, ACID ADDITION SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1997-10-16 | — | — | WO | disclosed |
| US-5652235-A | Method of using spiro piperidines to promote the release of growth hormone | MERCK & CO., INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996039140-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5536716-A | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | disclosed |
| EP-0615977-A1 | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO. INC. (US) | 1994-09-21 | — | — | EP | disclosed |
| WO-1994013696-A1 | SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | ATM 461/4885SIGMAR1 3281/4885HDAC3 58/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | ATM 266/4885SIGMAR1 4792/4885HDAC3 606/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | ATM 266/4885SIGMAR1 4792/4885HDAC3 606/4885 |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | CFTR, PKD2, PKD1 | ATM 3996/4885SIGMAR1 3898/4885HDAC3 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.